Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00513552|
Recruitment Status : Unknown
Verified August 2007 by Medstar Health Research Institute.
Recruitment status was: Recruiting
First Posted : August 8, 2007
Last Update Posted : August 8, 2007
Crohn's disease is a chronic inflammatory disorder of the gastrointestinal tract. The origin of Crohn's disease remains unknown and there is no curative therapy, either medical or surgical, for this gut disorder.
It is believed that an infectious agent is important in the development of Crohn's disease. The similarity of Crohn's disease to the animal form of ileitis, termed Johne's disease, supports the possibility that both disorders are caused by exposure to Mycobacterium avium paratuberculosis or MAP. Multiple investigators have demonstrated good clinical responses of patients with Crohn's disease to treatment with triple antibiotic therapy directed against mycobacterial infection.
The hypothesis of this protocol is that triple antibiotic therapy is useful as a medical therapy for patients with Crohn's disease. The aim of this study is to examine the response of patients with Crohn's disease who are not receiving therapy with biological agents to triple antibiotic therapy.
|Condition or disease||Intervention/treatment||Phase|
|Crohn's Disease||Drug: Rifabutin, Clarithromycin, and Clofazimine||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||20 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Treatment of Crohn's Disease With an Antibiotic Regimen Directed Against Mycobacterium Avium Paratuberculosis|
|Study Start Date :||January 2007|
|Estimated Study Completion Date :||March 2008|
- Drug: Rifabutin, Clarithromycin, and Clofazimine
Rifabutin 150 mg by mouth twice daily, Clarithromycin 250 mg by mouth twice a day, and Clofazimine 100 mg by mouth each morning
- Clinical remission by a decline in Crohns disease activity index to <151 [ Time Frame: 6 Months ]
- Clinical improvement using inflammatory bowel disease quality of life questionnaire [ Time Frame: 6 Months ]
- Endoscopic improvement using Crohn's disease endoscopic activity index [ Time Frame: 6 Months ]
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00513552
|Contact: Timothy R Koch, M.D.||firstname.lastname@example.org|
|United States, District of Columbia|
|Washington Hospital Center||Recruiting|
|Washington, District of Columbia, United States, 20010|
|Principal Investigator: Timothy R Koch, MD|
|Principal Investigator:||Timothy R Koch, MD||Washington Hospital Center|